menu
    • menu
    [{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Rumpus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Oncology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Denovo Biopharma \/ Rumpus Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Rumpus Therapeutics"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Oncology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Denovo Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denovo Biopharma \/ Aytu BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Denovo Biopharma \/ Aytu BioPharma"},{"orgOrder":0,"company":"Rumpus Therapeutics","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rumpus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumpus Therapeutics \/ Aytu BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Rumpus Therapeutics \/ Aytu BioPharma"},{"orgOrder":0,"company":"Qiagen","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Qiagen \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ Denovo Biopharma"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aytu BioPharma \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPharma \/ Canaccord Genuity"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aytu BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Enzastaurin

    Menu

    Enzastaurin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aytu BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aytu BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin

                            Details : AR101 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways.

                            Brand Name : AR101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 16, 2022

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aytu BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aytu BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Canaccord Genuity

                            Deal Size : $10.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering

                            Details : The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS).

                            Brand Name : AR101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 15, 2022

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Canaccord Genuity

                            Deal Size : $10.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Qiagen

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qiagen

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzastaurin,Rituximab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Denovo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-...

                            Details : Under the agreement, QIAGEN will develop a diagnostic assay that can detect the Denovo Genomic Marker 1 (DGM1) in DLBCL patients, a biomarker discovered by Denovo that predicts the responsiveness to DB102, also known as enzastaurin.

                            Brand Name : Kinenza

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 09, 2021

                            Lead Product(s) : Enzastaurin,Rituximab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Denovo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Denovo Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Denovo Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Aytu BioScience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Denovo's Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharma

                            Details : Aytu BioPharma has acquired substantially all the assets of Rumpus Therapeutics, including Rumpus' option to license DB102 for rare genetic pediatric onset or congenital disorders outside of oncology from Denovo Biopharma LLC.

                            Brand Name : DB102

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 13, 2021

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Aytu BioScience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Rumpus Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Rumpus Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Aytu BioScience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeu...

                            Details : Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications. Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS).

                            Brand Name : AR101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 12, 2021

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Aytu BioScience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Denovo Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Denovo Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzastaurin,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation For DB102 in Patients with Newly-Diagnosed Glioblastoma (GBM)

                            Details : Denovo plans to conduct a randomized, double-blind, placebo-controlled Phase 3 pivotal study of enzastaurin in combination with temozolomide, both during and following radiation therapy, in newly-diagnosed glioblastoma patients.

                            Brand Name : Kinenza

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 17, 2020

                            Lead Product(s) : Enzastaurin,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Denovo Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Denovo Biopharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Rumpus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinic...

                            Details : Rumpus Therapeutics gains the option to acquire an exclusive license to develop and commercialize DB102 worldwide for rare genetic pediatric onset or congenital disorders outside of oncology.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 21, 2020

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Rumpus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth